5 Biotech Momentum Names as Healthcare Holds a Bid

Healthcare has crept back into leadership on recent market strength. The Health Care Select Sector SPDR fund, $XLV State Street Health Care Select Sector SPDR ETF $154.68 , has shown about an 8% gain over the past month on recent market data, even as fund flows have been uneven. That mix, stronger price with mixed flows, argues for selectivity within the sector rather than broad exposure.

Within that frame, a handful of smaller biotech and therapeutics names have built momentum on tangible news or near term data windows. These are not buy and forget holdings. Small and mid cap biotech is event driven, and binary outcomes can overwhelm technicals. But for momentum with risk control traders, the combination of strong multi month returns and specific milestones offers a defined way to manage exposure.

Tango Therapeutics: Combo data fuels the move

$TNGX Tango Therapeutics, Inc. $32.16 has been one of the sector’s eye catchers, up about 249% year to date on recent figures. The stock’s latest leg higher tracks to company updates pointing to multiple readouts in the back half of 2026 and, notably, a company report of a 92% objective response rate in pancreatic cancer for vopimetostat combined with a RAS pathway inhibitor. RAS refers to a family of genes that regulate cell growth and are often mutated in cancer, so blocking that signaling is a major drug target in pancreatic tumors.

Why it matters: the thesis here is a pipeline shifting from early signals to randomized testing in high need tumors. What would disprove it is a weaker than expected showing in later stage studies or delays on the disclosed timelines. Until then, the stock trades like a data driven rerating with defined catalysts into late 2026.

Liquidia: Commercial inflection after approval

Rare disease player $LQDA Liquidia Corporation $68.01 is riding a commercial step up after the U.S. Food and Drug Administration approved Yutrepia inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Shares have advanced about 393% over the past year, and the current watch item is execution on launch, payer uptake, and competitive dynamics among treprostinil products.

What could change the story: any signs of slower than expected adoption or pricing pressure as competitors respond. For traders, the recent trend backs momentum, but position size should reflect that commercialization curves can be lumpy.

Absci: AI drug creation with partners

$ABSI Absci Corporation $7.00 has posted a roughly 196% three month advance alongside rising interest in artificial intelligence (AI) enabled discovery platforms. The company’s collaboration with AstraZeneca to apply Absci’s generative AI to an oncology antibody program supports the partner funding model that can extend runway while sharpening focus on high value targets.

What to watch: additional partner updates, program progress toward the clinic, and any evidence that AI generated designs improve timelines or success rates. The momentum case here hinges on credible partner validation and capital discipline while the platform matures.

Spyre Therapeutics: Multiple 2026 readouts

$SYRE Spyre Therapeutics, Inc. $83.41 has climbed about 147% year to date. The company laid out a concentrated 2026 slate, including its six proof of concept plan with accelerated Part A readouts starting in the second quarter from the SKYLINE ulcerative colitis platform trial, plus basket trial readouts across rheumatology indications expected in the fourth quarter of 2026.

Why it matters: clustered proof of concept catalysts can reset valuation if early efficacy is compelling. The flip side is stacked event risk. If early signals disappoint, momentum can unwind quickly. Traders should map position sizes to the readout calendar.

Oruka Therapeutics: Near term psoriasis updates

$ORKA Oruka Therapeutics, Inc. $67.71 has gained about 119% over three months. The near term focus is psoriasis program visibility. Management pointed to initial 16 week EVERLAST A data in the second quarter and longer term updates in the second half of 2026. Oruka also highlighted potential dosing interval advantages in its inflammatory and immunology pipeline.

The trading read: a clean second quarter update could extend the trend, while a muddled signal would argue for patience. With event risk front loaded, keep risk boxes tight into data.

How to use this watch list

This is a tactical basket for momentum with risk control. The common thread is strong multi month returns backed by tangible clinical or commercial milestones within the next two to three quarters. That makes these names suitable for staged entries and disciplined exits around data and launch checkpoints rather than open ended core positions.